A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases

被引:23
作者
Lee, AS [1 ]
Finkielman, JD [1 ]
Peikert, T [1 ]
Hummel, AM [1 ]
Viss, MA [1 ]
Specks, U [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Pulm & Crit Care Med, Thorac Dis Res Unit, Rochester, MN 55905 USA
关键词
ANCA; capture ELISA; proteinase; 3; Wegener's granulomatosis;
D O I
10.1016/j.jim.2005.09.004
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Testing for antineutrophil cytoplasmic antibodies (ANCA) reacting with protemase 3 (PR3) is part of the routine diagnostic evaluation of patients with small vessel vasculitis. For PR3-ANCA detection, capture ELISAs are reported to be superior to direct ELISAs. Standard capture ELISAs, in which PR3 is anchored by anti-PR3 monoclonal antibodies (moAB), have two potential disadvantages. First, the capturing moAB may compete for epitopes recognized by some PR3-ANCA, causing occasional false-negative results. Second, the capture of recombinant PR3 mutant molecules becomes unpredictable as modifications of specific conformational epitopes may not only affect the binding of PR3-ANCA, but also the affinity of the capturing anti-PR3 moAB. Here, we describe a new capture ELISA, and its application for PR3-ANCA detection. This new assay is based on the standardized capture of a variety of different carboxy-terminally c-myc tagged recombinant ANCA target antigens using anti-c-mvc coated ELISA plates. Antigen used include c-myc tagged human rPR3 variants (mature and pro-form conformations), mouse mature rPR3 and human recombinant neutrophil elastase. This new anti-c-myc-capture ELISA for PR3-ANCA detection has an intra- and inter-assay coefficient of variation of 3.6% to 7.7%, and 15.8% to 18.4%, respectively. The analytical sensitivity and specificity for PR3-ANCA positive serum samples were 93% and 100%, respectively when rPR3 with mature conformation was used as target antigen, and 83% and 100% when the pro-enzyme conformation was employed. In conclusion, this new anti-c-myc capture ELISA compares favorably to our standard capture ELISA for PR3-ANCA detection,enables the unified capture of different ANCA target antigens through binding to a c-myc tag, and allows capture of rPR3 mutants necessary for PR3-ANCA epitope mapping studies. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:62 / 72
页数:11
相关论文
共 31 条
[1]  
BINI P, 1992, J IMMUNOL, V149, P1409
[2]   Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA [J].
Capizzi, SA ;
Viss, MA ;
Hummel, AM ;
Fass, DN ;
Specks, U .
KIDNEY INTERNATIONAL, 2003, 63 (02) :756-760
[3]  
CHANG L, 1995, CLIN EXP IMMUNOL, V102, P112
[4]   Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study [J].
Csernok, E ;
Holle, J ;
Hellmich, B ;
Willem, J ;
Tervaert, C ;
Kallenberg, CGM ;
Limburg, PC ;
Niles, J ;
Pan, GL ;
Specks, U ;
Westman, K ;
Wieslander, J ;
De Groot, K ;
Gross, WL .
RHEUMATOLOGY, 2004, 43 (02) :174-180
[5]   A critical evaluation of commercial immunoassays for antineutrophil cytoplasmic antibodies directed against proteinase 3 and myeloperoxidase in Wegener's granulomatosis and microscopic polyangiitis [J].
Csernok, E ;
Ahlquist, D ;
Ullrich, S ;
Gross, WL .
RHEUMATOLOGY, 2002, 41 (11) :1313-1317
[6]   The crystal structure of PR3, a neutrophil serine proteinase antigen of Wegener's granulomatosis antibodies [J].
Fujinaga, M ;
Chernaia, MM ;
Halenbeck, R ;
Koths, K ;
James, MNG .
JOURNAL OF MOLECULAR BIOLOGY, 1996, 261 (02) :267-278
[7]   Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site [J].
Griffith, ME ;
Coulthart, A ;
Pemberton, S ;
George, AJT ;
Pusey, CD .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 123 (01) :170-177
[8]  
Hoffman GS, 1998, ARTHRITIS RHEUM-US, V41, P1521, DOI 10.1002/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO
[9]  
2-A
[10]  
HOLLE JU, IN PRESS ANN RHEUM D